Hima Atluri, MD
@himaglobina
Asst Professor @LurieCancer via @MDAndersonNews, @WashUIMres and @UMKCmedschool I Still waiting on an I-70 World Series I Interested in #MedEd and #Leukemia
ID: 836383963
20-09-2012 21:19:32
437 Tweet
813 Followers
746 Following
Thank you AK Eisfeld for visiting MD Anderson Cancer Center .. for your outstanding talk on myeloid sarcoma and for sharing your beautiful data with us. Seeing this story come to life has been a true joy. looking forward to ongoing and future exciting collaborations together.
Excited to be in San Diego for the 2nd annual CAR T and Bispecific meeting Excellent speaker lineup Looking forward to interactive discussion cc Dr Raje Noopur Raje Dr Neelapu MD Education Ryan Fitzpatrick Christopher Flowers bshah
Had an amazing weekend at the CAR T and bispecifics meeting in San Diego! Thank you Nitin Jain Noopur Raje and Dr. Neelapu! MD Education Jayastu Senapati @twitterlessNeha
Happy to share our commentary in @practiceupdate shorturl.at/ipwMN with Hima Atluri, MD on this very timely and interesting paper on targeting molecular MRD by Ing Soo Tion, Andrew Wei and team in Journal of Clinical Oncology shorturl.at/gCKLS Thank you Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 for the opportunity
🎙️ The Fellows Panel is underway at #HOPLive24! Megan Melody MD, MS Alexandra Rojek Seda Tolu Zaker Schwabkey, MD Hima Atluri, MD Hannah Goulart buff.ly/3xNw3wF
My takeaway front the #CML session with Dr. Jabbour, Mikkael A. Sekeres MD, MS and Sangeetha Venugopal MD,MS : *our definitions of response (ELN, NCCN) need to be updated * be patient before you switch TKI, allow time for deep molecular response * and most importantly : thank you Mark Cuban #HOPLive24
Fantastic unanswered questions in #AML session by Naval Daver, M.D. Sanam Loghavi, MD صنم لغوی 🔬🧬 Rami komrokji Mikkael A. Sekeres MD, MS Great discussion focused on importance and optimal sequencing of therapies for patients w AML - particularly those with targetable mutations! #HOPLive24
Sanam Loghavi, MD صنم لغوی 🔬🧬 also discussed #MRD in #AML: "Not all MRD is created equally," she said. "Not all the assays are as sensitive. So, you really have to know what you're using and how to interpret the data in the context of the greater picture."
Looking forward to presenting investigator initiated phase 2 trial of time-limited pirtobrutinib + venetoclax + obinutuzumab as frontline Rx for pts with CLL at European Hematology Association EHA 2024 Bill Wierda, MD, PhD MD Anderson Cancer Center library.ehaweb.org/eha/2024/eha20…
“Rather than telling the patient to come every day for five days for an IV chemotherapy treatment, we can just prescribe a pill they can take at home,” says our Dr. Nitin Jain. Learn about it here: brnw.ch/21wJVqo Nitin Jain Tapan Kadia Hima Atluri, MD #leukemia #EndCancer
👉👉Last clinic day for Hima Hima Atluri, MD with us. Will miss her. Wonderful clinician, researcher and colleague. All the very best in your new adventure at Northwestern Medicine 🙏🏽🙏🏽👏👏 cc Naveen Pemmaraju, MD Tapan Kadia Jessica Altman, MD
Adding venetoclax to intensive chemotherapy with cladribine, idarubicin, and cytarabine resulted in deep and durable remissions in young, fit patients with newly diagnosed #AML or #MDS, according to a study presented by Tapan Kadia of MD Anderson Cancer Center. 📰 buff.ly/42ozFT8
👉👉👉Delighted to share our brand new original report 🚨 led by our Dr Hannah Goulart & Naveen Pemmaraju, MD ➡️oral DAC+VEN for #BPDCN || MD Anderson Cancer Center #endcancer tandfonline.com/doi/full/10.10…
EP6 is live on YouTube and major platforms! Community oncologist Ben Fangman, MD, physician-scientist Kyle Concannon, MD, and patient Samantha M discuss local vs academic care. Ep 06: Academic Vs. Community Oncology | Cracking Cancer Podcast youtu.be/1d0F2AMjhhY?si… via YouTube
Wonderful podcast featuring two former co-fellows about the critical relationships between community and academic oncology! So proud of Ben Fangman, MD and @kyleconcannon4 - thanks for highlighting this important topic!